Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01898273 · ClinicalTrials.gov registry record · Phase 2
Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma
A Phase 2 study, sponsored by Cellectar Biosciences.
- Terminated
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT01898273 is a Phase 2 study that was terminated before completion, run by Cellectar Biosciences. The registered enrollment target is 7 participants.
The verdict
NCT01898273, a Phase 2 study, was terminated before completion, sponsored by Cellectar Biosciences.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The primary objective of this trial is to determine the optimal dose and imaging time point(s) of I-124-CLR1404 in subjects with newly diagnosed and recurrent glioma to be used in future trials.
Interventions
- DRUG I-124-CLR1404
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2014-02 |
| Est. Completion | 2015-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01898273
The ClinicalTrials.gov registry entry for NCT01898273 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Cellectar Biosciences, which has 10 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which I-124-CLR1404 is the first listed.
NCT01898273 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01898273 about?
NCT01898273 is a clinical study titled "Imaging Trial With I-124-CLR1404 in Patients With Newly Diagnosed or Recurrent Glioblastoma". The primary objective of this trial is to determine the optimal dose and imaging time point(s) of I-124-CLR1404 in subjects with newly diagnosed and recurrent glioma to be used in future trials.
What is the current status of trial NCT01898273?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2014-02. Estimated completion is 2015-12.
What interventions are being tested in trial NCT01898273?
The interventions under investigation include: I-124-CLR1404 (DRUG).
Who is sponsoring clinical trial NCT01898273?
This trial is sponsored by Cellectar Biosciences, which has 10 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.